Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05581147

Thyroid Function and Structure in Klinefelter Syndrome

This is a longitudinal retrospective study for the evaluation of thyroid function and structure in patients with Klinefelter syndrome compared to healthy controls and patients affected by chronic lymphocytic thyroiditis.

Recruiting

Interested in participating?

Request Info

Key information

About this study

This is a longitudinal retrospective study for the evaluation of thyroid function and structure in patients with Klinefelter syndrome compared to healthy controls and patients affected by chronic lymphocytic thyroiditis (CLT).

The investigators will retrospectively enroll patients with Klinefelter syndrome followed at the host institution and will retrieve data with regards to peripheral hormone levels (thyroid function) and ultrasonographic appearance (thyroid structure) according to pubertal status and gonadal status. Data will be compared with male age- and pubertal stage-matched euthyroid controls, as well as with male patients affected by CLT.

The primary outcome will be the thyroid function compared to healthy controls, by the assessment of peripheral blood TSH, free T3 (fT3) and free T4 (fT4) levels according to pubertal status (pre-pubertal, pubertal and adult subjects) as well as according to gonadal status (eugonadal subjects, hypogonadal subjects and subjects receiving testosterone replacement therapy [TRT]).

Secondary Outcome Measures will be:

Thyroid function indexes (fT3/fT4 ratio, fT4/TSH ratio, TSH*fT4 product)

Quantitative ultrasonographic thyroid structure parameters, comprising: thyroid volume and echogenicity index, as well as the echotexture parameters of homogeneity and entropy evaluated by Gray Levels Co-occurrence Matrices (GLCM).

In vitro assay of testosterone and estradiol effects on deiodinase type 2 (DIO2) activity in a rat pituitary cell line.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a confirmed diagnosis of classic, non-mosaic 47,XXY Klinefelter syndrome based on a peripheral blood 97 karyotype analysis;
  • Availability of thyroid function test results (TSH, fT3, and fT4) and/or thyroid US imaging;
  • Availability of concurrent clinical data.

Exclusion criteria

  • Presence of other known genetic conditions or chromosomal abnormalities;
  • Use of levothyroxine or other drugs that are either active on the hypothalamic-pituitary-thyroid (HPT) axis or that may interfere with thyroid function tests;
  • History of previous surgery or radiotherapy on the thyroid or pituitary glands;
  • Current or previous T therapy (for the pre-pubertal and pubertal groups).

Treatment and study plan

Primary outcomes

  1. Peripheral blood TSH concentration

    Time frame: Through study completion, an average of 6 years

    Thyroid function will be assessed by peripheral blood TSH levels, taking into account pubertal status (pre-pubertal, pubertal and adult subjects) as well as to gonadal status (eugonadal subjects, hypogonadal subjects and subjects receiving TRT).

  2. Peripheral blood fT3 concentration

    Time frame: Through study completion, an average of 6 years

    Thyroid function will be assessed by peripheral blood free T3 (fT3) levels, taking into account pubertal status (pre-pubertal, pubertal and adult subjects) as well as to gonadal status (eugonadal subjects, hypogonadal subjects and subjects receiving TRT).

  3. Peripheral blood fT4 concentration

    Time frame: Through study completion, an average of 6 years

    Thyroid function will be assessed by peripheral blood free T4 (fT4) levels, taking into account pubertal status (pre-pubertal, pubertal and adult subjects) as well as to gonadal status (eugonadal subjects, hypogonadal subjects and subjects receiving TRT).

Secondary outcomes

  1. Peripheral deiodinase 2 (DIO2) activity

    Time frame: Through study completion, an average of 6 years

    The investigators will derive the the fT3/fT4 ratio as a surrogate marker of peripheral deiodinase 2 (DIO2) activity.

  2. Pituitary sensitivity sensitivity to thyroid hormones

    Time frame: Through study completion, an average of 6 years

    The investigators will derive the fT4/TSH ratio as surrogate marker of pituitary sensitivity.

  3. Thyroid hormone resistance index

    Time frame: Through study completion, an average of 6 years

    The investigators will derive the TSH*fT4 product as a surrogate marker of thyroid hormone resistance.

  4. Thyroid volume

    Time frame: Through study completion, an average of 6 years

    The investigators will assess ultrasonography-derived thyroid volume (in mL) by the sum of the left and right lobe volumes, derived by the ellissoid formula (d1 x d2 x d3 x 0,5233).

  5. Quantitative thyroid echogenicity

    Time frame: Through study completion, an average of 6 years

    The investigators will assess the ultraonographic thyroid echogenicity index, derived by the histogram mean of thyroid parenchyma in a standardized scan, normalized by the histogram mean of the pre-thyroid muscles.

  6. Thyroid echotexture (homogeneity)

    Time frame: Through study completion, an average of 6 years

    The investigators will assess the ultrasonographic thyroid parenchymal echotexture via the analysis of Grey Levels Co-occurrence Matrices (GLCM) second-order parameter homogeneity (or IDM).

  7. Thyroid echotexture (entropy)

    Time frame: Through study completion, an average of 6 years

    The investigators will assess the ultrasonographic thyroid parenchymal echotexture via the analysis of Grey Levels Co-occurrence Matrices (GLCM) second-order parameter entropy.

  8. In vitro assay of deiodinase type 2 (DIO2) activity

    Time frame: At study end (May 2022).

    The investigators will assess in vitro modulation of DIO2 activity by sex hormones testosterone and 17-beta estradiol in a rat pituitary cell line (GH4C1) by using a thyroid hormone-responsive artificial promoter (TRE3Tk-Luc).

Study contacts

Contact information is provided by the study sponsor or research team.

Andrea M Isidori, MD, PhD

CONTACT

[email protected]

0039649970711

Sponsors and collaborators

Lead sponsor

University of Roma La Sapienza

Other

Registry information

Official study title

Thyroid Function and Structure in Klinefelter Syndrome (THINKS)

Acronym: THINKS

Important dates

Study start
2007
Primary completion
2019
Study completion
2026
First posted
Oct 14, 2022
Registry last updated
Mar 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.